Investor Presentation H1 2023

99 Investor presentation First six months of 2023 Ziltivekimab phase 2b RESCUE trial was successfully completed In the RESCUE trial, ziltivekimab QM showed reduction in hsCRP at all dose levels % change¹ 12 weeks of treatment 0% -5% -20% 2 End of treatment -3% -40% -60% . • • Data from RESCUE trial Novo NordiskⓇ Ziltivekimab QM showed reductions in inflammation biomarkers³ Ziltivekimab QM appeared to have a safe and well-tolerated profile Addressing the residual risk of CVD for more than 5 million patients with ASCVD, CKD, and inflammation4 The phase 3 cardiovascular outcomes trial was initiated in Q3 2021 -80% * -77% * -88% * -100% -92% placebo Iziltivekimab 15 mg * -79% * * • -91% -93% I ziltivekimab 7.5 mg ziltivikemab 30 mg 1 Primary endpoint was the median percent change in hsCRP, * Indicates statistical significance, p < .0001 2 End of treatment is defined as the average of values at week 23 and week 24 3 Inflammation biomarkers include: Fibrinogen, serum amyloid A, haptoglobin and NTproBNP 4 Inflammation is defined as c-reactive protein levels greater than 2 Zilti: Ziltivekimab; QM: Once-montly; hsCRP: High-sensitivity C-reactive protein; CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; CKD: Chronic kidney disease

View entire presentation